Literature DB >> 12544702

Acute clinical hepatitis by immune restoration in a human immunodeficiency virus/hepatitis B virus co-infected patient receiving antiretroviral therapy.

Isabelle Rouanet1, Hélène Peyrière, Jean-Marc Mauboussin, Nicolas Terrail, Denis Vincent.   

Abstract

We describe a human immunodeficiency virus (HIV)-infected patient with chronic active hepatitis B. The patient presented with acute clinical hepatitis during highly active antiretroviral therapy concomitant with immunovirological improvement of HIV infection. The hepatitis resolved within a few weeks despite the pursuit of antiretroviral drugs. Hepatitis B tests, which remained unchanged after two cycles of interferon alfa therapy and continuous administration of lamivudine, were improved with the clearance of hepatitis B virus (HBV) early antigen (HBeAg), the detection of antibody to HBV early antigen (HBeAb) and the undetectability of serum HBV DNA. Several months after this episode, HBV and HIV tests are still controlled. Copyright 2003 Lippincott Williams & Wilkins

Entities:  

Mesh:

Year:  2003        PMID: 12544702     DOI: 10.1097/00042737-200301000-00017

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  4 in total

Review 1.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

2.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

Review 3.  Evaluation and treatment of the patient coinfected with hepatitis B and HIV.

Authors:  Ellen Kitchell; Mamta K Jain
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

Review 4.  [Immune restoration inflammatory syndromes].

Authors:  M Stoll; H Heiken; G M N Behrens; R E Schmidt
Journal:  Internist (Berl)       Date:  2004-08       Impact factor: 0.743

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.